Patents by Inventor Sunil Kumar Mandal

Sunil Kumar Mandal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS
    Publication number: 20220251094
    Abstract: The present invention discloses a fused heterocyclic compound of formula (I), wherein, R1, Y, Q, A, G, m and E are as defined in the detailed description. The present invention further discloses methods for their preparation and use of the compounds of formula (I) as a pest control agent.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Applicant: PI INDUSTRIES LTD.
    Inventors: Gagan KUKREJA, Vikas KUMAR, Lalit Kumar JENA, Jeevan Singh VERMA, Rohit SAXENA, Sunil Kumar MANDAL, Vishwanath GADE, Kiran K C, Ravikumar Suryanarayana SARAGUR, Alexander G.M. KLAUSENER
  • IDO inhibitors
    Patent number: 9765018
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: September 19, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. Williams, Amy C. Hart, Jennifer Inghrim
  • IDO inhibitors
    Patent number: 9758492
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: September 12, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Syngene International Limited
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • Tricyclic compounds as anticancer agents
    Patent number: 9751879
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, Jr., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160326173
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 10, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160318928
    Abstract: The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 3, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • IDO INHIBITORS
    Publication number: 20160200674
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Application
    Filed: August 26, 2014
    Publication date: July 14, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160176864
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: June 23, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • IDO INHIBITORS
    Publication number: 20160137595
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: July 1, 2014
    Publication date: May 19, 2016
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. William, Amy C. Hart, Jennifer Inghrim
  • Diaminocyclohexane compounds and uses thereof
    Patent number: 8815909
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: August 26, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: William R. Ewing, Yeheng Zhu, Chongqing Sun, Yanting Huang, Maheswaran Sivasamban Karatholuvhu, Scott A. Bolton, Laxman Pasunoori, Sunil Kumar Mandal, Philip M. Sher
  • DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF
    Publication number: 20130184284
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.
    Type: Application
    Filed: July 16, 2012
    Publication date: July 18, 2013
    Inventors: William R. Ewing, Yeheng Zhu, Chongqing Sun, Yanting Huang, Maheswaran Sivasamban Karatholuvhu, Scott A. Bolton, Laxman Pasunoori, Sunil Kumar Mandal, Philip M. Sher